The company is set to report its latest quarterly earnings on Monday, May 4th, with a consensus estimate of $0.41 EPS.
Integra LifeSciences Holdings Corporation (IART) is currently priced at $10.5, experiencing a decrease of 19 cents (-1.78%) from the previous close. The trading volume stands at $120,747, representing a 15% deviation from the average.
The latest quarterly earnings report on Wednesday, February 25th, fell short of expectations with an EPS of -2.22 cents. The company faces challenges in revenue generation and profitability.
The company shows a net increase in cash of $2.86 million, with operating cash flow at $11.82 million and debt repayment of $-24.48 million. Despite challenges, the company maintains a healthy cash position of $235 million.
Integra LifeSciences reported revenue of $434.93 million, with a gross profit of $215.36 million. However, the company incurred a net loss of $-1.70 million, reflecting operational inefficiencies.
Key financial metrics reveal challenges, including a negative net profit margin of -0.392% and a high effective tax rate of 139.54%. The company's return on equity and return on assets are also negative, indicating profitability concerns.
The balance sheet shows total assets of $3.60 billion, with total liabilities at $2.56 billion. The company faces significant long-term debt of $1.73 billion, impacting its financial stability.
This real-time financial report highlights the challenges facing Integra LifeSciences Holdings Corporation, emphasizing the need for strategic operational improvements to drive profitability and sustainable growth.
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.